Material Characterization and Control and Knowledge Management Considerations for Continuous Manufacturing with the Real-Time Release Material Characterization.

Slides:



Advertisements
Similar presentations
Training Workshop on Pharmaceutical Development with a Focus on Paediatric Medicines / October |1 | Training Workshop on Pharmaceutical Development.
Advertisements

2-5. Formulation Development Issues: Solid Orals Satish Mallya January, 2011.
National Institute for Pharmaceutical Technology and Education (NIPTE) Interim Risk Assessment Report.
The Gamlen Tablet Press (GTP) Michael Gamlen Gamlen Tableting Ltd.
Methods of tablet manufacturing
1 Implementation of Quality by Design (QbD): Status, Challenges and Next Steps Moheb M. Nasr, Ph.D. Office of New Drug Quality Assessment (ONDQA), OPS,
Stability data required by WHO-PQP Mercy Acquaye.
The NIPTE-FDA Excipients Database hosted at pharmaHUB Ann Christine Catlin Rosen Center for Advanced Computing Purdue University June 14, 2012.
S-SENCE Signal processing for chemical sensors Martin Holmberg S-SENCE Applied Physics, Department of Physics and Measurement Technology (IFM) Linköping.
Formulation design Manufacturing process design Virtual patient population (PBPK, PDPK) API physical properties Dosage parameters Target.
How to Define Design Space Lynn Torbeck. Overview Why is a definition important? Definitions of Design Space. Deconstructing Q8 Definition. Basic science,
World Health Organization
Determine impurity level in relevant batches1
Pharmtech Contract Services Offered by the Division of Pharmaceutical Technology.
Quality by Design (QbD) in Product Development
Process Analytical Technologies Subcommittee Product and Process Development: An Industry Perspective David Rudd PhD Process Technology GlaxoSmithKline.
MIT PHARMACEUTICAL MANUFACTURING INITIATIVE (PHARMI) PHARMACEUTICAL MANUFACTURING: NEW TECHNOLOGY OPPORTUNITIES.. G.K.Raju, Ph.D. Executive Director, Pharmaceutical.
World Health Organization
PAT Validation Working Group Process and Analytical Validation Working Group Arthur H. Kibbe, Ph.D. Chair June 13, 2002.
Learnings from Pre-approval Joint Inspection of a GSK QbD Product with US-FDA & EMA and the application of Continuous Verification 17 May 2011, Beijing,
How characterization of excipient physical and chemical properties helps build quality into drug product Dr Brian A Carlin FMC BioPolymer.
Validation of Analytical Method
FDA Regulatory Perspective on Continuous Manufacturing
Achieving and Demonstrating “Quality-by-Design” with Respect to Drug Release/dissolution Performance for Conventional or Immediate Release Solid Oral Dosage.
Helping the World Be Well through Innovative Manufacturing
Slide 1 May 2008 Training Workshop on Pharmaceutical Development with focus on Paediatric Formulations Mumbai, India Date: May 2008 QUALITY BY DESIGN.
ACPS Advisory Committee Meeting October , 2002 ACPS Advisory Committee Meeting October , 2002 Scientific Considerations of Polymorphism in.
Quality by Design Application of Pharmaceutical QbD for Enhancement of the Solubility and Dissolution of a Class II BCS Drug using Polymeric Surfactants.
Establishing Drug release/Dissolution Specifications – QBD Approach Moheb M. Nasr, Ph.D. Office of New Drug Quality Assessment (ONDQA), OPS, CDER Advisory.
Excipient QbD Concepts to Enhance the Development of Robust Drug Products Priscilla S. Zawislak Global Regulatory Affairs Manager - Ashland Inc. Chair.
DEVELOPMENT OF QUALITY BY DESIGN (QBD) GUIDANCE ELEMENTS ON DESIGN SPACE SPECIFICATIONS ACROSS SCALES WITH STABILITY CONSIDERATIONS Fluid Bed Drying Small.
Title: Plan for Approach to the Understanding and Predicting Excipient Properties and Functionality NIPTE - National Institute of Pharmaceutical Technology.
Applications of Analytical Chemistry in Pharmaceuticals Corey M. Chong 10Mar10.
Module 1, Part 3: Process validation Slide 1 of 22 © WHO – EDM – 12/2001 Validation Part 3: Process validation Supplementary Training Modules on Good Manufacturing.
NIPTE-FDA Collaborative Case Study On Model-based Design Space Development Across Scales & with Stability Considerations Preliminary Design Space 1.
OM: if PS is small, add diluent and use blend style Final Formulation: calculate capsule size, % excipients, and final formulation DF: choose excipients.
Blend Uniformity - PQRI Research
Quality by Design (QbD) Myth : An expensive development tool ! Fact : A tool that makes product development and commercial scale manufacturing simple !
1-7.The ICH Q8 “Minimal Approach” to Pharmaceutical Development
1 Regulatory Aspects of Pharmaceutical Excipients PQRI Workshop Nick Buhay Acting Director Division of Manufacturing and Product Quality Office of Compliance.
Critical Material Properties for Pharmaceutical Dosage Forms - Industry Perspective Tony Hlinak Abbott Laboratories North Chicago, IL.
Excipient Composition and Performance-Related Properties of Excipients Chris Moreton, Ph.D. FinnBrit Consulting IPEC-Americas FDA Seminar, October 21,
Some Future Developments Brian Carlin, Ph.D FMC Chris Moreton, Ph.D FinnBrit Consulting IPEC-Americas FDA Seminar, October 21,
Satish Mallya January 20-22, |1 | 2-3. Pharmaceutical Development Satish Mallya Quality Workshop, Copenhagen May 18-21, 2014 May 18-21,2014.
Excipient Variability Sources, Importance and Potential Impact Chris Moreton, Ph.D Past Chair IPEC-Americas Partner – FinnBrit Consulting
Searching For Root Causes Under Pressure Using Data Visualization to Focus Investigations Dan Pilipauskas Pfizer Inc.
General Aspects of Quality assessment of multisource interchangeable medicines Rutendo Kuwana Technical Officer, WHO, Geneva Training workshop: Assessment.
开发报批美国 FDA 的仿制药 与相关问题探讨 上海复星普适医药科技有限公司何平. 内容提要 开发仿制药的重要性和机遇 开发仿制药的重要性和机遇 开发仿制药的挑战 开发仿制药的挑战 申报仿制药的分类 申报仿制药的分类 仿制药研发团队 仿制药研发团队 仿制药的研发过程 仿制药的研发过程 QbD 在制剂开发中怎么体现.
QbD Technologies: Workshop for Risks Management Incorporating Risk Management for Technology Transfer.
Product & Process Working Group February 26, 2002.
QbD Technologies: Workshop for Risks Management Incorporating Risk Management for Technology Transfer.
Integration of Excipients into the Design of Experiments for Pharmaceutical Product and Design Space Development Chris Moreton, Ph.D. FinnBrit Consulting.
Faculty of Pharmacy and Medical Sciences Al-Ahliyya Amman University
QbD and Excipient Variability: A Perspective from a User Company Joseph Kushner, IV, Ph.D., Principal Scientist, Drug Product Design Groton, CT
Proposal for a Manufacturing Classification System (MCS)
Physico-chemical Control of Dosage Forms
A QbD Approach to Process Development: Defining Critical Quality Attributes and Evaluating Criticality Across Scales Carl A. Anderson, Duquesne University.
Results and Discussion
Enabling direct compaction at high drug loading via dry coating of APIs: Towards a predictive framework Presenter(s): Kuriakose T. Kunnath, NJIT Research.
,Branko Vranic1, Nada Tarek2 ,V. Frost 3, G. Betz1
Dissolution testing and in vitro in vivo correlation of conventional and SR preparations Formulation development and optimization is an ongoing process.
Evaluation of tablet Lab 5.
Evaluation of tablet Lab 5.
IPSA (Industrial Problem Solving Ability )
Dr Dehghan M. H Professor in Pharmaceutics,
QUALITY BY DESIGN Training Workshop on Pharmaceutical Development with focus on Paediatric Formulations Mumbai, India Date: May 2008.
Tablet Dosage Form Lab 1.
Implementation of Quality by Design (QbD): Status, Challenges and Next Steps Moheb M. Nasr, Ph.D. Office of New Drug Quality Assessment (ONDQA), OPS, CDER.
Quality by Design.
Evaluation of tablet Lab 5.
Presentation transcript:

Material Characterization and Control and Knowledge Management Considerations for Continuous Manufacturing with the Real-Time Release Material Characterization and Control and Knowledge Management Considerations for Continuous Manufacturing with the Real-Time Release October 4, 2016 FDA, Silver Spring, MD Stephen W. Hoag, Ph.D. University of Maryland, Baltimore School of Pharmacy Phone

Outline Role of material properties in model development – Identification of CQA – PAT example – RTRT data fusion models Database structure and usage – PharmaHub – Database views – Applications

Dosage Form Variability API Dosage Forms Excipients Manufacturing Processing Conditions Spec. range

Which Raw Material Inputs → CQA Critical Quality Attributes Hardness Disintegration time Dissolution CU/mixing Stability Excipient Properties Crystal form Particle size Bulk density Etc. Relationships Not well understood

Raw Data Hidden Info & Patterns Data Mining Raw Data Def: Discovery of previously unknown information and patterns from set of data Stage 1 Define problem or subject of study Stage 2 Select data Visualize Data Remove noise, & Irrelevant Data Stage 3 Data preprocessing Stage 4 Data Analysis Data Mining Analysis of Results Assimilation of Knowledge

Sources of Excipient Variability  Intentional (designed into excipient) – i.e., different grades and vendors – Manufactures produce to improve performance – Many examples  MCC, HPMC, lactose, et al. – Important to understand for:  Optimizing a formulation performance, in vitro and during production  Make regulatory decisions, e.g., excipient substitution and change control  Random – Lot-to-lot variation  Introduced from all factors disused previously – Within a lot variation (container-to-container)  During production process parameters can drift – Especially continuous process where a lot maybe several days of production – Important to understand: so can produce robust formulations

PH-200 PH-102 SCG PH-102 PH-101 PH-105 PH-103PH-113 PH-112 Decrease moisture content NMT 1.5% NMT 2% NMT 3% NMT 5% Particle size 180 um 150 um 100 um 50 um 20 um PH-302 PH g/cc 0.4g/cc Loose bulk density NMT= not more than FMC Intentional Variation—Grades of MCC

Intentional Variability– Manufacturers of MCC Manufactures GradesParticle Size, µ mMoisture, % Loose Bulk Density, g/cc FMC Avicel PH JRS Vivapur Emcocel 50M AKC PH UF KG KG FMC Avicel PH JRS Vivapur Emcocel 90M AKC PH FMC = FMC B IOPOLYMERS AKC = Asahi Kasei Corporation JRS = J Rettenmaier & Söhne GmbH and Co.KG

Tracking of Random Variability Track random variability overtime and plot in histogram

Example of Lubricants  Formulation type - binary mixture – MCC ductile / plastic – Lactose intermediate – Dical brittle  Formulation properties – Ejection force (EF) – Breaking force (BF) – Disintegration time (DT)  Excipient properties – Density, true, poured and tapped – Loss on drying (LOD) – Solid state crystal type via DSC – Particle size and size distribution (PSD) – Specific surface area (SSA) – Fatty acid analysis – Microscopy

SampleSourceGradeLot No.Sample No. 1Covidien Mallinckrodt (CM) NA 2Covidien Mallinckrodt (CM) NA 3Covidien Mallinckrodt (CM) NA 4Covidien Mallinckrodt (CM)2257MO Covidien Mallinckrodt (CM)2257MO6062NA 6Covidien Mallinckrodt (CM)1729JO Covidien Mallinckrodt (CM)5716LO4224NA 8Covidien Mallinckrodt (CM)1726MO8729NA 9Peter Greven (PG)MF-2-V-BIC917002NA 10Peter Greven (PG)MF-2-VC019038NA 11Peter Greven (PG)MF-3-VCO16795NA 12Spectrum (S)MgStOX0283NA 13Spectrum (S)MgStWQ0272NA MgSt Variability Random Samples Collected from Vendors

Mg Stearate Specs. MF-2V SSA 6-10 m 2 /g D  m MF-3V SSA 8-12 m 2 /g D  m MF-2-V-BI SSA 6-8 m 2 /g D  m

Sample Mean Particle Size (um) Particle Size Span Specific Surface Area (m2/g) ± ± ± ± ± ± ± ± ± ± ± ± ± ± ± ± ± ± ± ± ± ± ± ± ± ± 0.03 Property differences between Mg Stearate samples

Lubricity of Mg Stearate

Solid State Characterization Forms: Anhydrous, monohydrate or dihydrate Dihydrate MonohydrateMixture

Excipient Variability & Performance Lactose Formulation, manufactured under identical conditions

PCA Analysis of Differences Valid prediction for properties such as Disintegration time Requiring analysis of material properties

ICH Q8/Q9/Q10 IMPLEMENTATION  I. Low-Impact Models: – Support product and/or process development  e.g., formulation optimization  II. Medium-Impact Models: – Assuring product quality but not sole indicator of product quality  e.g., most design space models, many in-process controls  III. High-Impact Models: – Model prediction is a significant indicator of product quality  e.g., chemometric model for product assay, dissolution, etc.

Spray Coating Beads Drug Layered Bead Spray Coated Bead Cured Bead Polymer Spray Coating Coat Drying & Curing Bead CMA/CQA - Thickness - Uniformity - Water content - Extent of curing API Layer Uncured EC coat Cured EC coat - API Content - API Homogeneity - Particle Size CPP - Air flow - Air temp - Curing time - LOD - Atomization - Spray rate - Air flow - Air temp. Models API assay Process Efficiency Moisture Content Curing Time Dissolution Rate

1) Evaporative Drying & Ordering 2) Particle Deformation 3) Coalescence & Polymer Inter-diffusion Not to scale Latex Particle Interface Rate is very Temp. Dependent T ~ Tg

Inlet Air V (m 3 /h) Spraying T Curing T 1 h = -2 2 h = -1 3 h = 0 4 h = +1 5 h = Paper 2

Curing and Dissolution rate

Product Temp. Curing Time Curing Temp. Air Volume Relative Humidity NIR of Spraying Process NIR of Curing Process Spraying Scores Parafa PCA Parafc PAC Curing Scores Process Param. Spraying ProcessCuring Process Data Fusion Spraying Scores Air Volume Curing Temp. Curing Time Relative Humidity PLS Model For Dissolution Dissolution Results

Dissolution 1Hour Parafac Decomposition Parafac = Parallel Factor Analysis Parafac is similar to 3D multidimensional PCA and process time is the 3 rd dimension -Dimensions are: time, wavelength and batch No.

Excipients Database Where to Host the Database ? pharmaHUB: a cyber infrastructure developed at Purdue University to support digital scholarship, dissemination, collaboration and outreach for the pharmaceutical engineering community.

Analysis Tools make decisions and solve problems Analysis Tools make decisions and solve problems Derivations & Plots of Measurements histograms, yield loci, powder flow function, frequency & cumulative distributions Derivations & Plots of Measurements histograms, yield loci, powder flow function, frequency & cumulative distributions Measurements raw data, chemical and test descriptions Measurements raw data, chemical and test descriptions Catalogs excipients, vendors, products, lots, test methods, equipment, properties Catalogs excipients, vendors, products, lots, test methods, equipment, properties Web Interface

Database Structure Excipients - MCC Products - PH101 Lots - Lot # 1 Properties - particle size Test method - Light scattering Equipment - Malvern ← USP compendial category ← Actual product on the market

A Publicly Available Database Excipients Database

A Publicly Available Database Excipients Database

A Publicly Available Database Excipients Database

A Publicly Available Database Excipients Database

The Mechanical Property Group Particle Size Distribution True Density Bulk Density Cohesiveness Elastic Modulus Compactibility Brittleness 32 A.Hlinak, NIPTE-NIST Meeting, April, 2005

Development Lots Based upon random selection of lots: Domain of prior Experience: typical production lots 3 lots used for development can tell if develop formulation using typical material Source: Kindly supplied by Joe Kushner

Supplier’s Data User’s Data Data MiningDatabase User Friendly Web based Interface Targeted Experiments to Support Database Relational Modeling Literature Data Database Management Tools User feedback

Acknowledgements  FDA & NIPTE for funding  Ting Wang  Ann Christine Catlin  Sumudinie Fernando  Sudheera R. Fernando  Carl Wassgren  Kristine Alston  Linas Mockus  Vadim Gurvich  Paribir Basu  Individuals with invaluable advice  FMC, Brian Carlin  Pfizer, Bruno Hancock  Roquette, Leon Zhou  Colorcon Dave Schoneker  IPEC  And many others